Flex Pharma (FLKS) Tops Q3 EPS by 7c

Flex Pharma (NASDAQ: FLKS) reported Q3 EPS of ($0.65), $0.07 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $586 thousand versus the consensus estimate of $110 thousand.

For earnings history and earnings-related data on Flex Pharma (FLKS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'